Search
Filter Results
Displaying 261–270 of 723 for “Visions 2020”
-
Jan 25, 2023
Foundation Fighting Blindness to Host PRPH2 and Associated Retinal Diseases Workshop
Session to have special translational research emphasis on PRPH2 and inherited macular dystrophies.
-
Dec 17, 2021
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
The Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
-
May 10, 2021
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
Nearly 50 years after its inception, the Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for blinding retinal diseases, unveils a rebranded chapter program, “Lulie’s Next Chapter for Light & Vision.”
-
Oct 21, 2020
SparingVision Raises €44.5 Million for Gene-Independent RP Therapy
The company is planning a clinical trial for its emerging neuroprotective treatment in 2021
-
Refsum disease is an inherited condition that causes vision loss, absence of the sense of smell, and a number of other symptoms.
-
Sep 11, 2018
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
On September 4, 2018, seven researchers, including six previously funded by the Foundation, were recognized with the prestigious 2018 Antonio Champalimaud Vision Award for their contributions to the advancement of blindness-reversing RPE65 gene therapies.
-
Jul 5, 2018
Retinal Regeneration: Releasing Your Inner Salamander
Many research groups from around the world are investigating ways to create new photoreceptors from stem cells for transplantation into the retina for vision restoration.
-
Leber Congenital Amaurosis (LCA)
LCA is a group of inherited retinal diseases causing blindness or severe vision loss in early childhood.
-
Jan 17, 2018
Clinical Trial to Launch for System Combining Optogenetics and Eyewear
The French biotech GenSight Biologics has received regulatory authorization in the UK to launch the PIONEER Phase 1 \ 2 clinical trial for its GS030 system — a light-sensing gene therapy (optogenetics) coupled with eyewear, which enhances visual stimulation.